|
|
AMP Advocacy
AMP Lobbies for
Equitable Reimbursement
AMP has been vigorously advocating with members of Congress
for several months to revise or reject legislation that
would eliminate the 14-day waiting period for a wide
spectrum of molecular tests - for laboratories that are
independent of the hospital where the specimen was collected
and not under any arrangements. This legislation first
appeared as H.R. 1699 (Altmire, et al.) and S. 1220 (Specter
& Wyden) and most recently as the Wyden #D10 Amendment to
the Chairman’s Mark of the Senate Finance Committee’s health
care reform bill. The proposed legislation provides an
incentive for hospitals to cease performing these molecular
tests in favor of outsourcing them to remove the cost from
the DRG. The CAP, which has also been fighting the
legislation, recently joined AMP to form a coalition that
now is five organizations strong.
Click here to read the
most recent letter – sent to Sen. Max Baucus.
AMP Comments to the SACGHS on October 8
AMP took the opportunity to reiterate its position on gene
patents, direct-to-consumer marketing of genetic testing,
and genetic nondiscrimination to the Secretary’s Advisory
Committee on Genetics, Health & Society (SACGHS) on October
8. Click here
to read AMP’s comments.
|